UK cost agency backs Celgene bone marrow drug in change of tack

LONDON, Aug 20 (Reuters) - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.